#Eli Lilly — FinScans

Release 📈 Stocks

Eli Lilly Reports Positive EBGLYSS Data for Atopic Dermatitis Treatment

October 5, 2026 (30 minutes ago)

Eli Lilly shares gain as new clinical data for EBGLYSS confirms long-term efficacy and reduced topical treatment needs for patients suffering from…

LLY

🌍 AMERICAS Read More →

Release 📈 Stocks

Eli Lilly Gains FDA Approval for Jaypirca to Treat CLL and SLL Patients

October 2, 2026 (2 days ago)

Eli Lilly expands its oncology footprint as the FDA approves Jaypirca for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,…

LLY

🌍 AMERICAS Read More →

News 📈 Stocks

Eli Lilly's Orforglipron Hits Primary Endpoints in Phase 3 ACHIEVE-4 Trial

October 1, 2026 (4 days ago)

Eli Lilly's oral GLP-1 drug orforglipron demonstrates significant cardiovascular safety and efficacy in phase 3 trials, showing a 16% lower risk of…

LLY

🌍 AMERICAS Read More →

Release 📈 Stocks

Eli Lilly Shares Rally as EloraTZP Data Shows 23.3% Weight Loss in Phase 2b

September 30, 2026 (4 days ago)

Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type…

LLY

🌍 GLOBAL Read More →

Release 📈 Stocks

Eli Lilly EBGLYSS Hits Primary Endpoint in Phase 3b Dermatitis Trial

September 30, 2026 (5 days ago)

Eli Lilly reports positive Phase 3b results for EBGLYSS, showing significant skin clearance and symptom relief for patients with hand and foot…

LLY

🌍 AMERICAS Read More →

Release 📈 Stocks

Eli Lilly Retatrutide Phase 3 Trial Shows 20.8% Weight Loss in Diabetics

September 30, 2026 (5 days ago)

Eli Lilly reports positive Phase 3 data for retatrutide, with patients achieving 20.8% weight loss over 80 weeks, strengthening the company's competitive…

LLY

🌍 AMERICAS Read More →

News 📈 Stocks

Investors Favor Eli Lilly Over Novo Nordisk After Downbeat Diagnosis

August 7, 2026 (59 days ago)

Investor sentiment turns bearish on Novo Nordisk while Eli Lilly gains favor amid shifting dynamics in the obesity-drug market.

LLY NVO

🌍 GLOBAL Read More →

News 📈 Stocks

Eli Lilly-Backed Scribe Therapeutics Soars 50% After Upsized IPO

July 24, 2026 (72 days ago)

Eli Lilly-backed biotech Scribe Therapeutics jumps 50% after upsized IPO, signaling renewed biotech IPO momentum.

SCRI LLY

🌍 US Read More →

News 📈 Stocks

Scribe Raises $128.7M in Upsized IPO Backed by Eli Lilly

July 24, 2026 (73 days ago)

Scribe Therapeutics, backed by Eli Lilly, raised $128.7 million in an upsized IPO, reflecting strong investor demand for biotech firms with major…

SCRIBE LLY

🌍 US Read More →

News 📈 Stocks

Eli Lilly-backed Scribe Therapeutics files for $107.2 million IPO

July 20, 2026 (76 days ago)

Scribe Therapeutics, with Eli Lilly’s backing, files for a $107.2 million IPO, highlighting gene-editing sector momentum and potential biotech IPO revival.

LLY

🌍 US Read More →

News 📈 Stocks

Novo, Lilly Brace for Ozempic Patent Expirations, Seek Next Blockbuster

May 28, 2026 (130 days ago)

Novo Nordisk and Eli Lilly stocks come under scrutiny as impending Ozempic and Mounjaro patent expirations threaten the GLP-1 revenue stream, forcing…

NVO LLY

Eli Lilly Loses Supreme Court Bid, Faces $194 Million Medicaid Payment

May 18, 2026 (139 days ago)

The Supreme Court rebuffed Eli Lilly's appeal of a $194 million Medicaid overpayment award, delivering a legal setback that threatens near-term earnings…

LLY XLV

🌍 US Read More →